Extended Abstract

Application of PASS Algorithm for the Discovery of New Trpa1 Antagonists [†]

Trif Comin *, Stancov Gheorghe, Nițulescu George Mihai, Olaru Octavian-Tudorel and Mihai Dragoș Paul

Faculty of Pharmacy, “Carol Davila” University of Medicine and Pharmacy, Traian Vuia 6, 020956 Bucharest, Romania; gheorghe.stancov@stud.umfcd.ro (S.G.); nitulescu_mihai@yahoo.com (N.G.M.); octav_olaru2002@yahoo.com (O.O.-T.); dragosm1992@gmail.com (M.D.P.)

* Correspondence: trifcosmin@gmail.com

[†] Presented at the 15th International Symposium “Priorities of Chemistry for a Sustainable Development” PRIOCHEM, Bucharest, Romania, 30th October–1st November 2019.

Published: 18 October 2019

Keywords: TRPA1; PASS; drug discovery

TRPA1 is a calcium ion channel found on the plasma membrane of many animal cells and it is involved in the cellular response to endogenous inflammatory mediators as well as a plethora of volatile irritants [1,2]. It is therefore a promising therapeutic target for the discovery of new treatments that relate to pain, irritation and sensory hypersensitivity [3–5]. PASS (Prediction of Activity Spectra for Substances) is a software used for predicting the biological activity profile of given molecules based on their chemical structure. The current study seeks to validate the use of PASS for the discovery of new therapeutic agents that act as TRPA1 antagonists.

The molecular structures of inhibitors with known IC₅₀ values were searched and downloaded from the ChEMBL database. With the use of PASS, we calculated “Pa” (the probability of a compound being active) and “Pi” (the probability of a compound being inactive). We evaluated the sensitivity of the method based on these values.

A number of 371 small molecules retrieved from ChEMBL database and their predicted activity spectra were analyzed. We identified the optimal threshold for finding new TRPA1 antagonists. The method was used to confirm new inhibitory structures based on previous repurposing studies.

The PASS software can be used for further studies regarding the discovery of new TRPA1 inhibitors.

References

1. Zygmunt, P.M.; Högestätt, E.D. Trpa1. In *Mammalian Transient Receptor Potential (TRP) Cation Channels*; Springer: Berlin/Heidelberg, Germany, 2014; pp. 583–630.
2. McNamara, C.R.; Mandel-Brehm, J.; Bautista, D.M.; Siemens, J.; Deranian, K.L.; Zhao, M.; Hayward, N.J.; Chong, J.A.; Julius, D.; Moran, M.M.; et al. TRPA1 mediates formalin-induced pain. *Proc. Natl. Acad. Sci. USA* **2007**, *33*, 13525–13530.
3. Fajardo, O.; Meseguer, V.; Belmonte, C.; Viana, F. TRPA1 channels mediate cold temperature sensing in mammalian vagal sensory neurons: pharmacological and genetic evidence. *J. Neurosci.* **2008**, *31*, 7863–7875.

4. Petrus, M.; Peier, A.M.; Bandell, M.; Hwang, S.W.; Huynh, T.; Olney, N.; Jegla, T.; Patapoutian, A. A role of TRPA1 in mechanical hyperalgesia is revealed by pharmacological inhibition. *Mol. Pain* **2007**, *1*, 40.
5. Mihai, D.P.; Nitulescu, G.M.; Ion, G.N.D.; Ciotu, C.I.; Chirita, C.; Negres, S. Computational Drug Repurposing Algorithm Targeting TRPA1 Calcium Channel as a Potential Therapeutic Solution for Multiple Sclerosis. *Pharmaceutics* **2019**, *11*, 446.

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).